



## Chapter 1 Epidemiology and Prevention

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply the basic principles of epidemiology and prevention of cancer to the care of oncology patients.
- Analyze the evidence supporting recommendations for cancer prevention.
- Distinguish intrinsic and extrinsic factors that affect cancer susceptibility.

### Continuing Education Credit

2.25 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*™
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

#### AUTHOR:

Stephen M. Schwartz, PhD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA

# ASCO-SEP<sup>®</sup>

## PEER REVIEWERS:

Electra D. Paskett, PhD, Ohio State University, Columbus, OH

Melinda L. Irwin, PhD, MPH, Yale University, New Haven, CT

## QUESTION WRITERS AND REVIEWERS:

Electra D. Paskett, PhD, Ohio State University, Columbus, OH

Melinda L. Irwin, PhD, MPH, Yale University, New Haven, CT

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, KeyQuest, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Stephen M. Schwartz, PhD, MPH (A): No relationships to disclose

Electra D. Paskett, PhD (R, QW): Stock and Other Ownership Interests- Pfizer, Meridian Bioscience Inc., Pfizer (I), Meridian Bioscience Inc (I); Research funding- Pfizer (Inst), Merck (Inst)

Melinda L. Irwin, PhD, MPH (R, QW): No relationships to disclose



### **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

### **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

### **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 2.25 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

### **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

### **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.

# ASCO-SEP<sup>®</sup>

## Chapter 2 Molecular Biology

### Description

ASCO-SEP<sup>®</sup> is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply the basic principles of molecular biology of cancer to the care of oncology patients.
- Explain how different therapeutic approaches target hallmarks in cancer development.

### Continuing Education Credit

2.75 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*<sup>™</sup>
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

#### AUTHOR:

Mark E. Burkard, MD, PhD, University of Wisconsin, Madison, WI

#### PEER REVIEWERS:

Andrew Nixon, PhD, Duke University, Durham, NC

# ASCO-SEP<sup>®</sup>

Scott Haake, MD, Vanderbilt University, Nashville, TN

## QUESTION WRITERS AND REVIEWERS:

Andrew Nixon, PhD, Duke University, Durham, NC

Scott Haake, MD, Vanderbilt University, Nashville, TN

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Mark E. Burkard, MD, PhD (A): Consulting or Advisory Role- Pointcare Genomics, Strata Oncology, Novartis; Research Funding- Abbvie (Inst), Strata Oncology (Inst), Puma Biotechnology (Inst), Loxo (Inst), Merck (Inst), Arcus (Inst), Apollomics (Inst), Elevation Oncology (Inst), Genentech (Inst); Patents, Royalties, Other Intellectual Property- Patent for implantable/localized drug delivery device that can sample tumor microenvironment and deliver drug; Patent for method to detect recombination events with CRISPR-mediated editing; Patent for conducting expansion microscopy without specialized equipment

Andrew Nixon, PhD (R, QW): Consulting or Advisory Role- GlaxoSmithKline, Leap Therapeutics, Promega, Lilly, Adjuvont Therapeutics; Research Funding- TRACON Pharma (Inst), Medpacto, Inc. (Inst), Seattle Genetics (Inst), Genentech/Roche (Inst), AstraZeneca/MedImmune (Inst), HTG Molecular Diagnostics (Inst), Promega (Inst), OncoMed (Inst); Patents, Royalties, Other Intellectual Property- Patent Pending (Inst), Patent (Inst)



Scott Haake, MD (R, QW): Expert Testimony- Nature's Bounty

### **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

### **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

### **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 2.75 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

### **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

### **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 3 Clinical Pharmacology

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply the basic principles of clinical pharmacology to the care of oncology patients.
- Explain common drug-associated toxicities and drug-drug interactions.

### Continuing Education Credit

1.25 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*™
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

#### AUTHOR:

Phuong Cham Nguyen, PharmD, University of California San Francisco, San Francisco, CA

# ASCO-SEP<sup>®</sup>

## PEER REVIEWERS:

Shivaani Kummar, MD, FACP, Oregon Health and Science University Department of Medicine, Portland, OR

Suwicha Limvorasak, BCOP, PharmD, Cedars-Sinai Medical Center, Los Angeles, CA

## QUESTION WRITERS AND REVIEWERS:

Inas Abuali, MD, Massachusetts General Hospital, Boston, MA

Suwicha Limvorasak, BCOP, PharmD, Cedars-Sinai Medical Center, Los Angeles, CA

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, KeyQuest, Decipher, Guidepoint Global, Bionest Partners Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Phuong Cham Nguyen, PharmD (A): No relationships to disclose

Shivaani Kummar, MD, FACP (R): Stock and Other Ownership Interests- PathomIQ, Arxeon (I); Consulting or Advisory Role- Cadila Pharmaceuticals (I), Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GMBH, Harbour Biomed, Springworks, Gilead, Mirati, EcoR1; Research Funding- Bristol-Myers Squibb (Inst), Dynavax (Inst), Pfizer (Inst), Loxo (Inst), Corvus Pharmaceuticals (Inst), Plexxikon (Inst), Jounce Therapeutics (Inst), ADC Therapeutics (Inst), Advenchen Laboratories (Inst), Incyte (Inst); Taiho Pharmaceutical (Inst), Bayer (Inst), Astex Pharmaceuticals (Inst), Seattle Genetics



# ASCO-SEP<sup>®</sup>

(Inst), Amgen (Inst), Genome & Company (Inst), Moderna Therapeutics (Inst), ORIC Pharmaceuticals (Inst), Elevation Oncology (Inst), Vincerx Pharma (Inst), Day One Therapeutics (Inst); Travel, Accommodations, Expenses- Bayer

Suwicha Limvorasak, BCOP, PharmD (R, QW): Research Funding- Pfizer

Inas Abuali, MD (QW): No relationships to disclose

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 1.25 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

# ASCO-SEP<sup>®</sup>

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 4 Principles of Immuno-oncology and Biologic Therapy

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply the basic principles of immuno-oncology and biologic therapy to the care of oncology patients.
- Apply knowledge of mechanisms of action and common adverse effects to select appropriate immunotherapy or biologic agent for patients with cancer.

### Continuing Education Credit

2.75 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*™
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

#### AUTHORS:

L. Elizabeth Budde, MD, PhD, City of Hope National Medical Center, Duarte, CA

# ASCO-SEP<sup>®</sup>

Lisa Butterfield, PhD, University of California, San Francisco, CA

## PEER REVIEWERS:

Christos Fountzilas, MD, Roswell Park Cancer Institute, Buffalo, NY

Claire Friedman, MD, Memorial Sloan Kettering Cancer Center, New York, NY

## QUESTION WRITERS AND REVIEWERS:

Christos Fountzilas, MD, Roswell Park Cancer Institute, Buffalo, NY

Ulka Vaishampayan, MBBS, University of Michigan, Ann Arbor, MI

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

L. Elizabeth Budde, MD, PhD (A): Consulting or Advisory Role- Roche/Genentech, Kite/Gilead, Novartis, BeiGene; Research Funding- Merck, Amgen, Mustang Bio, AstraZeneca; Patents, Royalties, Other Intellectual Property- CCR4 CAR T cells for treatment of patients with CCR4 positive cancer, CD33CAR for treatment of patients with CD33+ acute myeloid leukemia; Travel, Accommodations, Expenses- Roche/Genentech, Kite/Gilead, AstraZeneca

Lisa Butterfield, PhD (A): Stock & Other Ownership Interests- RAPT Therapeutics, Pyxis, Cytomix; Honoraria- SapVax, Torque, Roche/Genentech, Adaptimmune, DCPrime; Consulting or Advisory Role-

# ASCO-SEP<sup>®</sup>

Calidi Biotherapeutics, Western Oncolytics, Pyxis, CytomX Therapeutics, Khloris Biosciences, RAPT Therapeutics

Christos Fountzilas, MD (R, QW): Research Funding- Merck (Inst), Lilly (Inst), MedImmune (Inst), Astellas Pharma (Inst), Rafael Pharmaceuticals (Inst), Incyte (Inst), Puma Biotechnology (Inst), Pfizer (Inst), Kinex (Inst), Seattle Genetics (Inst), Corcept Therapeutics (Inst), Ipsen (Inst), ERYTECH Pharma (Inst), Syndax (Inst), Taiho Oncology (Inst), Kadmon (Inst), Dragonfly Therapeutics (Inst)

Claire Friedman, MD (R): Honoraria- OncLive/MJH Life Sciences, Aptitude Health; Consulting or Advisory Role- Seagen, Arch Oncology, Bristol-Myers Squibb; Research Funding- Bristol-Myers Squibb (Inst), Genentech (Inst), Merck (Inst), Daiichi Sankyo/UCB Japan (Inst); Uncompensated Relationships- Genentech, Merck

Ulka Vaishampayan, MBBS (QW): Consulting or Advisory Role- Pfizer, Exelixis, Bayer, Bristol-Myers Squibb/Medarex, Merck Serono, Advanced Accelerator Applications, Helsinn Therapeutics, Aveo; Speakers' Bureau- Pfizer, Bayer, Exelixis; Research Funding- Bristol-Myers Squibb, Merck KGaA

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 2.75 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

# ASCO-SEP<sup>®</sup>

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 5 Clinical Trials and Biostatistics

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply the basic principles of statistics and clinical trials to the care of oncology patients.
- Critically review levels of evidence in clinical research and compare different study designs.

### Continuing Education Credit

2.25 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*™
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

#### AUTHORS:

A. Craig Lockhart, MD, MHS, Medical University of South Carolina - Hollings Cancer Center, Charleston, SC

# ASCO-SEP<sup>®</sup>

Susan Halabi, PhD, Duke Cancer Institute, Durham, NC

## PEER REVIEWERS:

Gary H. Lyman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA

William Barlow, PhD, Cancer Research and Biostatistics (CRAB), Seattle, WA

## QUESTION WRITERS AND REVIEWERS:

Gary H. Lyman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA

William Barlow, PhD, Cancer Research and Biostatistics (CRAB), Seattle, WA

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

A. Craig Lockhart, MD, MHS (A): Consulting or Advisory Role- Novartis; Research Funding- Amgen (Inst)

Susan Halabi, PhD (A): Employment- ASCO TAPUR

Gary Lyman, MD (R, QW): Honoraria- Sandoz, Partners Healthcare, Bristol-Myers Squibb, Seattle Genetics, Teva; Consulting or Advisory Role- G1 Therapeutics, Sandoz, Samsung Bioepis, BeyondSpring



# ASCO-SEP<sup>®</sup>

Pharmaceuticals, TEVA, Jazz, Partner Therapeutics, ER Squibb, MSD, Seattle Genetics, Kallyope, Spectrum Pharmaceuticals, Frensenius Kabi; Research Funding- Amgen (Inst)

William Barlow, PhD (R, QW): Research Funding- Merck (Inst), AstraZeneca (Inst)

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 2.25 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

# ASCO-SEP<sup>®</sup>

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 6 Genetic Testing of Hereditary Cancer Syndromes

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply the basic principles of genetic testing of hereditary cancer syndromes to the care of oncologic patients.
- Analyze hereditary cancer predisposition and principles for cancer risk assessment.

### Continuing Education Credit

1.75 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits™*
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

#### AUTHORS:

Brian H. Shirts, MD, PhD, University of Washington, Seattle, WA

# ASCO-SEP<sup>®</sup>

Colin C. Pritchard, MD, PhD, University of Washington, Seattle, WA

Heather Hampel, MS, LGC, City of Hope National Medical Center, Duarte, CA

## PEER REVIEWERS:

Joanne Jeter, MD, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Sommer Hayden, MS, CGC, Saint Joseph Mercy Cancer Center, Ann Arbor, MI

## QUESTION WRITERS AND REVIEWERS:

Joanne Jeter, MD, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Sommer Hayden, MS, CGC, Saint Joseph Mercy Cancer Center, Ann Arbor, MI

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Brian H. Shirts, MD (A): No relationships to disclose

Colin C. Pritchard, MD, PhD (A): Consulting or Advisory Role- Promega, AstraZeneca, Sana Biotechnology; Research Funding- Color Genomics (I)

# ASCO-SEP<sup>®</sup>

Heather Hampel, MS, LGC (A): Stock and Other Ownership Interests- Genome Medical, GI OnDemand; Consulting or Advisory Role- InVitaе, Genome Medical, Promega

Joanne Jeter, MD (R, QW): Consulting or Advisory Role- Pfizer, Array BioPharma; Research Funding- Merck, Bristol-Myers Squibb (Inst); Travel, Accommodations, Expenses- Pfizer, Array BioPharma

Sommer Hayden, MS, CGC (R, QW): No relationships to disclose

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 1.75 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

# ASCO-SEP<sup>®</sup>

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## **Chapter 7 Cancer in the Older Patient**

### **Description**

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### **Learning Objectives**

- Apply the basic principles of cancer in the older cancer patient.
- Analyze the physiologic changes in the older patient and utilize the Geriatric Assessment tools.

### **Continuing Education Credit**

1 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*™
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### **Credit Expiration**

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### **EDITOR-IN-CHIEF:**

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### **ASSOCIATE EDITORS:**

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

#### **AUTHOR:**

Grant R. Williams, MD, University of Alabama, Birmingham, AL

Heidi D. Klepin, MD, MS, Wake Forest University, Winston-Salem, NC

# ASCO-SEP<sup>®</sup>

## PEER REVIEWERS:

Carolyn J. Presley, MD, MHS, The Ohio State University, Columbus, OH

Elizabeth H. Prsic, MD, Yale University, New Haven, CT

## QUESTION WRITERS AND REVIEWERS:

Elizabeth H. Prsic, MD, Yale University, New Haven, CT

Venu Madhav Konala, MD, King's Daughters Medical Center, Ashland, KY

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD: No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Heidi D. Klepin, MD, MS (A): Consulting or Advisory Role- Genentech, Pfizer; Patents, Royalties, Other Intellectual Property- UpToDate contributor; Uncompensated Relationships- Genentech

Grant R. Williams, MD (A): Honoraria- Carevive Systems, Cardinal Health

Carolyn J. Presley, MD, MHS (R): Consulting or Advisory Role- Potentia Metrics, OneLive

Elizabeth H. Prsic, MD (R, QW): No relationships to disclose





Venu Madhav Konala, MD (QW): Consulting or Advisory Role- Cardinal Health

### **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

### **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

### **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 1 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

### **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

### **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 8 Pain and Symptom Management

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply the basic principles of pain and symptom management to the care of oncology patients.
- Apply knowledge of the evidence supporting pain management guidelines among different disease areas.
- Prioritize and mitigate symptoms affecting the quality of life and relating to treatment, including acute and late adverse effects and comorbidities.

### Continuing Education Credit

2.5 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits™*
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

#### AUTHORS:

# ASCO-SEP<sup>®</sup>

Natalie A. Moryl, MD, Memorial Sloan Kettering Cancer Center, New York City, New York

Vinay G. Puttanniah, MD, Memorial Sloan Kettering Cancer Center, New York City, New York

## PEER REVIEWERS:

Amany Keruakous, MD, MS, Georgia Cancer Center, Augusta University, Augusta, GA

Janet L. Abraham, MD, Dana-Farber Cancer Institute, Boston, MA

## QUESTION WRITERS AND REVIEWERS:

Amany Keruakous, MD, MS, Georgia Cancer Center, Augusta University, Augusta, GA

Janet L. Abraham, MD, Dana-Farber Cancer Institute, Boston, MA

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Vinay G. Puttanniah, MD (A): No relationships to disclose

Natalia A. Moryl, MD (A): Consulting or Advisory Role- Collegium Pharmaceutical

Amany Keruakous, MD, MS (R, QW): No relationships to disclose



Janet L. Abraham, MD (R, QW): Consulting or Advisory Role- Pfizer/EMD Serono; Patents, Royalties, Other Intellectual Property- UpToDate, JHUP

### **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

### **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

### **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 2.5 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

### **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

# ASCO-SEP<sup>®</sup>

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 9 Palliative Care and Care at the End of Life

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply the basic principles of palliative care and care at the end of life to oncology patients.
- Critically review issues relevant to palliative care needs and communication with patients and their families.
- Explain the psychological changes during end-of-life care for a patient with cancer.

### Continuing Education Credit

2.25 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits™*
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

#### AUTHOR:

Pallavi Kumar, MD, MPH, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## PEER REVIEWERS:

Emily Martin, MD, University of California- Los Angeles, Los Angeles, CA

Jennifer S. Temel, MD, Massachusetts General Hospital, Boston, MA

## QUESTION WRITERS AND REVIEWERS:

Emily Martin, MD, University of California- Los Angeles, Los Angeles, CA

Jennifer S. Temel, MD, Massachusetts General Hospital, Boston, MA

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Pallavi Kumar, MD, MPH (A): Consulting or Advisory Role- Acceleron Pharma, Inc. (I), Amylyx Pharmaceuticals (I); Research Funding- Amicus Therapeutics (I), Amylyx Pharmaceuticals (I), Acceleron Pharma (I); Travel, Accommodations, Expenses: Acceleron Pharma (I), Amylyx Pharmaceuticals (I)

Emily Martin, MD (R, QW): No relationships to disclose

Jennifer S. Temel, MD (R, QW): No relationships to disclose

## Commercial Support



This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

### **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

### **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 2.25 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

### **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

### **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.





## Chapter 10 Breast Cancer

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of the basic epidemiology, natural history, and symptoms of breast cancer to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current treatment options for patients diagnosed with breast cancer and recommend approaches based on current evidence.

### Continuing Education Credit

4 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits™*
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHORS:

Rachel Sanford, MD, Memorial Sloan Kettering Medical Center, New York City, New York

Tiffany A. Traina, MD, Memorial Sloan Kettering Medical Center, New York City, New York

## PEER REVIEWERS:

Jennifer M. Specht, MD, University of Washington, Seattle, WA

Pavani Chalasani, MD, MPH, University of Arizona, Tucson, AZ

## QUESTION WRITERS AND REVIEWERS:

Bernard Tawfik, MD, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM

Jennifer M. Specht, MD, University of Washington, Seattle, WA

Joanne Jeter, MD, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Pavani Chalasani, MD, MPH, University of Arizona, Tucson, AZ

## **Disclosure of Relationships with Companies**

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

# ASCO-SEP<sup>®</sup>

Tiffany A. Traina, MD (A): Consulting or Advisory Role- Genentech/Roche, Pfizer, AstraZeneca, Merck, Puma Biotechnology, Athenex, Daiichi Sankyo, Ionis, Seattle Genetics, Eisai, Exact Sciences, Foundation Medicine, Ayala Pharmaceuticals, Gilead Sciences, Blueprint Medicines, Ellipses Pharma, Fuji Pharma, ITEos Therapeutics, Agendia; Research Funding- Eisai (Inst), Pfizer (Inst), Novartis (Inst), Innocrin Pharma (Inst), AstraZeneca (Inst), Astellas Pharma (Inst), Immunomedics (Inst), Genentech/Roche (Inst), Daiichi Sankyo (Inst), Carrick Pharm (Inst), Ayala Pharmaceuticals (Inst)

Rachel Sanford, MD (A): No relationships to disclose

Pavani Chalasani, MD, MPH (R, QW): Consulting or Advisory Role- AstraZeneca, NanoString Technologies, Bayer, HERON, Amgen, Asthenext, Eisai, Lilly, Puma Biotechnology, OncoSec, Atossa, BioTheranostics; Research Funding- Pfizer, Lilly, Carrick Therapeutics, Phoenix Molecular Designs, Genentech/Roche, Ventana Medical Systems, BioAtla, Zentalis, Amgen, Radius Health; Patents, Royalties, Other Intellectual Property- Provisional patent submitted for using Syndros for management of pain from bone metastases (Inst)

Jennifer M. Specht, MD (R, QW): Honoraria- Daiichi Sankyo; Consulting or Advisory Role- Daiichi Sankyo; Research Funding- Merck (Inst), Cascadian Therapeutics (Inst), Pfizer (Inst), Seattle Genetics (Inst), Genentech (Inst), Xencor (Inst), Abbvie (Inst); Travel, Accommodations, Expenses- Nektar

Bernard Tawfik, MD (QW): Other Relationship- Ipsen

Joanne Jeter, MD (QW): Consulting or Advisory Role- Pfizer, Array BioPharma; Research Funding- Merck, Bristol-Myers Squibb (Inst); Travel, Accommodations, Expenses- Pfizer, Array BioPharma

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 4 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

# ASCO-SEP<sup>®</sup>

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 11 Lung Cancer

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of the basic epidemiology, natural history, and symptoms of lung cancer to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current treatment options for patients diagnosed with lung cancer and recommend approaches based on current evidence.

### Continuing Education Credit

3.25 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits™*
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHOR:

Chad V. Pecot, MD, University of North Carolina, Chapel Hill, NC

## PEER REVIEWERS:

Saiama N. Waqar, MD, Washington University in St. Louis, St. Louis, MO

Sarah B. Goldberg, MD, MPH, Yale University, New Haven, CT

## QUESTION WRITERS AND REVIEWERS:

Badi El Osta, Winship Cancer Institute, Emory University, Atlanta, GA

Saiama N. Waqar, MD, Washington University in St. Louis, St. Louis, MO

Sarah B. Goldberg, MD, MPH, Yale University, New Haven, CT

## **Disclosure of Relationships with Companies**

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Chad V. Pecot, MD (A): Leadership- EnFuego Therapeutics; Stock and Other Ownership Interests- EnFuego Therapeutics; Consulting or Advisory Role- Medscape; Research Funding- Jazz Pharmaceuticals; Patents, Royalties, Other Intellectual Property- Methods and Compositions for Ligand delivery of oligonucleotides, Methods and Compositions using RNA Interference for inhibition of MYC

# ASCO-SEP<sup>®</sup>

and dual KRAS/MYC targeting, Methods and compositions using RNA Interference for inhibition of KRAS (Inst); Other Relationship: EnFuego Therapeutics

Saiama N. Waqar, MD (R, QW): Research Funding- Spectrum Pharmaceuticals (Inst), Lilly (Inst), Pfizer (Inst), Genentech/Roche (Inst), Daiichi Sankyo (Inst), Newlink Genetics (Inst), EMD Serono (Inst), Puma Biotechnology (Inst), Novartis (Inst), Xcovery (Inst), Synermore Biologics (Inst), Celgene (Inst), Vertex (Inst), Bristol-Myers Squibb (Inst), Stem CentRx (Inst), Hengrui Therapeutics (Inst), Checkpoint Therapeutics (Inst), Ignyta (Inst), AstraZeneca (Inst), ARIAD (Inst), Roche (Inst), Merck (Inst)

Sarah B. Goldberg, MD, MPH (R, QW): Consulting or Advisory Role- AstraZeneca/MedImmune, Bristol-Myers Squibb, Boehringer Ingelheim, Genentech/Roche, Sanofi Genzyme, Daiichi Sankyo, Regeneron, Blueprint Medicine, Takeda, Janssen; Research Funding- AstraZeneca, Boehringer Ingelheim, Merck (Inst), Genentech (Inst), Pfizer (Inst), Bristol-Myers Squibb (Inst), Spectrum Pharmaceuticals (Inst), Amgen (Inst)

Badi El Osta, MD (QW): Honoraria- OncLive; Research Funding- Merck (Inst), Novartis (Inst), Bristol-Myers Squibb Foundation (Inst)

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 3.25 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

# ASCO-SEP<sup>®</sup>

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.





## Chapter 12 Head and Neck Cancer

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of the basic epidemiology, natural history, and symptoms of head and neck cancer to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current treatment options for patients diagnosed with head and neck cancer and recommend approaches based on current evidence.

### Continuing Education Credit

2.5 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*™
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHOR:

Ranee Mehra, MD, University of Maryland Medical Center, Baltimore, MD

## PEER REVIEWERS:

Aartia K. Bhatia, MD, MPH, Yale University, New Haven, CT

Cristina P. Rodriguez, MD, University of Washington, Seattle, WA

## QUESTION WRITERS AND REVIEWERS:

Aartia K. Bhatia, MD, MPH, Yale University, New Haven, CT

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Ranee Mehra, MD (A): Stock and Other Ownership Interests- GlaxoSmithKline (I); Consulting or Advisory Role- Bayer, Rakuten Medical; Research Funding- AstraZeneca, Merck

Aartia K. Bhatia, MD, MPH (R, QW): Honoraria- Clinical Care Options, ASCO Direct; Consulting or Advisory Role- Sanofi/Regeneron, Merck; Research Funding- Boehringer Ingelheim

Cristina P. Rodriguez, MD (R): Consulting or Advisory Role- AstraZeneca (I), Beigene (I), Karyopharm Therapeutics (I), Kite Pharma (I), Incyte (I), Millennium Pharmaceuticals (I), ADC Therapeutics (I);



Research Funding- Merck (Inst), AstraZeneca/MedImmune (Inst), Bristol-Myers Squibb (Inst), Ignyta (Inst), Ayala (Inst), CUE Biopharma (Inst), Kura (Inst)

### **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

### **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

### **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 2.5 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

### **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

# ASCO-SEP<sup>®</sup>

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 13 Gastrointestinal Cancers

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of the basic epidemiology, natural history, and symptoms of gastrointestinal cancers to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current treatment options for patients diagnosed with gastrointestinal cancers and recommend approaches based on current evidence.

### Continuing Education Credit

4.5 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*™
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHORS:

Colin D. Weekes, MD, PhD, Massachusetts General Hospital, Boston, MA

N. Arvind Dasari, MD, University of Texas MD Anderson Cancer Center, Houston, TX

## PEER REVIEWERS:

Kristen K. Ciombor, MD, MCSI, Vanderbilt University, Nashville, TN

Sakti Chakrabarti, MD, Medical College of Wisconsin, Milwaukee, WI

## QUESTION WRITERS AND REVIEWERS:

Benjamin Weinberg MD, Georgetown University Hospital, Washington, DC

Kristen K. Ciombor, MD, MCSI, Vanderbilt University, Nashville, TN

Sakti Chakrabarti, MD, Medical College of Wisconsin, Milwaukee, WI

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Colin D. Weekes, MD, PhD (A): Honoraria- Celgene, Lilly, Bayer; Consulting or Advisory Role- Celgene, Merrimack, Ipsen; Research Funding- Millennium, Celgene, Bayer, Genentech/Roche, Abbvie,

# ASCO-SEP<sup>®</sup>

Lilly, AstraZeneca, Gilead Sciences, Ipsen, Halozyme, Deciphera Pharmaceuticals, Novartis, Actuate Therapeutics; Travel, Accommodations, Expenses- Lilly, Celgene, Bayer

N. Arvind Dasari, MD (A): Consulting or Advisory Role- Ipsen, Novartis, Voluntis, Lexicon, Hutchison Pharma, Personalis, Crinetics Pharmaceuticals; Research Funding- Novartis, Eisai, Hutchison Pharma, Merck, Guardant Health, Ipsen

Kristen K. Ciombor, MD, MCSI (R, QW): Consulting or Advisory Role- Bayer, Foundation Medicine, Taiho, Natera, Array BioPharma, Research To Practice, Merck, Pfizer; Research Funding- Pfizer (Inst), Boston Biomedical (Inst), MedImmune (Inst), Onyx (Inst), Bayer (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Merck (Inst), Novartis (Inst), Incyte (Inst), Amgen (Inst), Sanofi (Inst), Array BioPharma (Inst), Daiichi Sankyo (Inst), Nucana (Inst), Abbvie (Inst), Pfizer/Calithera (Inst); Travel, Accommodations, Expenses- Array

Sakti Chakrabarti, MD (R, QW): Honoraria- HalioDx, QED Therapeutics; Speakers' Bureau- Natera

Benjamin Weinberg, MD (QW): Employment- Apple (I); Stock and Other Ownership Interests- Apple (I); Honoraria- Rafael Pharmaceuticals; Consulting or Advisory Role- Bayer, HalioDx, AstraZeneca/Daiichi Sankyo; Speakers' Bureau- Lilly, Bayer, Taiho Pharmaceutical, Sirtex, HalioDx, Daiichi Sankyo, AstraZeneca; Research Funding- Novartis (Inst), Abbvie (Inst), Isofol Medical (Inst), Ipsen (Inst); Expert Testimony- AstraZeneca; Travel, Accommodations, Expenses- Caris Life Sciences, Boehringer Ingelheim

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 4.5 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

# ASCO-SEP<sup>®</sup>

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.





## Chapter 14 Genitourinary Cancers

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of the basic epidemiology, natural history, and symptoms of genitourinary cancers to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current treatment options for patients diagnosed with genitourinary cancers and recommend approaches based on current evidence.

### Continuing Education Credit

7 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*™
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHOR:

Joseph W. Kim, MD, Yale Cancer Center, New Haven, CT

Rahul A. Parikh, MD, PhD, University of Kansas Medical Center, Kansas City, KS

## PEER REVIEWERS:

Abhishek Tripathi, MD, Oklahoma University, Norman, OK

Benjamin L. Maughan, MD, PharmD, University of Utah, Salt Lake City, UT

## QUESTION WRITERS AND REVIEWERS:

Andrew Armstrong, MD, MS, Duke University, Durham, NC

Bradley McGregor, MD, Dana Farber Cancer Institute, Boston, MA

Dean Park MD, Walter Reed National Military Medical Center, Washington, DC

Mitchell Gross, MD, PhD, Lawrence J. Ellison Institute for Transformative Medicine of USC, Los Angeles, CA

Nancy Davis, MD, Vanderbilt Ingram Cancer Center, Nashville, TN

Regina Barragán-Carrillo, MD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

# ASCO-SEP<sup>®</sup>

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Joseph W. Kim, MD (A): Stock and Ownership Interests- Abiomed (I), Celgene (I), Johnson & Johnson (I); Consulting or Advisory Role- Voluntas, Sanofi, EMD Serono, Clovis; Research Funding- Immune Design

Rahul A. Parikh, MD, PhD (A): Stock and Ownership Interests- Myovant Sciences (I); Consulting or Advisory Role- Merck; Research Funding- Taiho Pharmaceutical; Patents, Royalties, Other Intellectual Property- Patents on DNA repair pathways in cancer. I do not receive any royalties for the same.

Abhishek Tripathi, MD (R): Honoraria- Urology Times; Consulting or Advisory Role- Foundation Medicine, Pfizer, Genzyme, EMD Serono, Exelixis, Dekka Biosciences; Research Funding- Clovis Oncology (Inst), Corvus Pharmaceuticals (Inst), Bayer, (Inst), EMD Serono (Inst), Aravive Inc (Inst), WindMIL Therapeutics (Inst), Exact Sciences (Inst), Pfizer (Inst)

Benjamin L. Maughan, MD, PharmD (R): Consulting or Advisory Role- Janssen Oncology; Exelixis, Tempus, Bristol-Myers Squibb, Astellas Medivation, Bayer, AVEO Oncology, Clovis, Merck, Peloton Therapeutics, Pfizer, Bavarian Nordic; Research Funding- Clovis Oncology (Inst), Bristol-Myers Squibb (Inst), Bavarian Nordic (Inst), Exelixis (Inst); Travel, Accommodations, Expenses- Exelixis

Andrew Armstrong, MD, MS (QW): Consulting or Advisory Role- Bayer, Dendreon, Pfizer, Astellas Scientific and Medical Affairs, AstraZeneca, Merck, Bristol-Myers Squibb, Janssen, FORMA Therapeutics, Novartis, Exelixis, Myovant Sciences, GoodRx; Research Funding- Dendreon (Inst), Bayer (Inst), Pfizer (Inst), Novartis (Inst), Janssen Oncology (Inst), Astellas Pharma (Inst), Gilead Sciences (Inst), Roche/Genentech (Inst), Bristol-Myers Squibb (Inst), Constellation Pharmaceuticals (Inst), Merck (Inst), AstraZeneca (Inst), BeiGene (Inst), Amgen (Inst), FORMA Therapeutics (Inst); Patents, Royalties, Other Intellectual Property- Circulating tumor cell novel capture technology (Inst); Travel, Accommodations, Expenses- Astellas Scientific and Medical Affairs

Bradley McGregor, MD (QW): Consulting or Advisory Role- Bayer, Seattle Genetics/Astellas, Exelixis, AstraZeneca, Astellas Pharma, Genentech/Roche, Nextar, Janssen Oncology, Pfizer, EMD Serono, Eisai, Dendreon, Bristol Myers-Squibb, Calithera Biosciences; Research Funding- Bristol-Myers Squibb (Inst), Exelixis (Inst), Calithera Biosciences (Inst), Seattle Genetics/Astellas (Inst), Pfizer/EMD Serono (Inst)

Dean Park, MD (QW): No relationships to disclose

Mitchell Gross, MD, PhD (QW): Employment- Lawrence Ellison for Transformative Medicine, LLC; Honoraria- Amgen; Research Funding- Clovis Oncology (Inst), Sumitomo Dainippon Pharma Oncology (Inst); Travel, Accommodations, Expenses- Amgen

Nancy Davis, MD (QW): Consulting or Advisory Role- Janssen Biotech; Research Funding- AstraZeneca (Inst), Roche (Inst), Pfizer (Inst), Merck (Inst), Incyte (Inst), Mirati Therapeutics (Inst), Seattle



Genetics/Astellas (Inst), Calithera Biosciences (Inst), Immunomedics (Inst), Bristol-Myers Squibb (Inst), Exelixis (Inst), Gilead Sciences (Inst)

Regina Barragán-Carrillo, MD (QW): No relationships to disclose

### **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

### **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

### **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 8 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

### **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

# ASCO-SEP<sup>®</sup>

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 15 Gynecologic Cancers

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of the basic epidemiology, natural history, and symptoms of gynecologic cancers to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current treatment options for patients diagnosed with gynecologic cancers and recommend approaches based on current evidence.

### Continuing Education Credit

1.5 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*<sup>™</sup>
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHOR:

Merry Jennifer Markham, MD, FACP, FASCO, University of Florida, Gainesville, FL

## PEER REVIEWERS:

Lainie P. Martin, MD, University of Pennsylvania, Philadelphia, PA

Paul J. Sabbatini, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

## QUESTION WRITERS AND REVIEWERS:

Paul J. Sabbatini, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

Yi-Chun Lee, MD, Catholic Health Services, Babylon, NY

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Merry Jennifer Markham, MD, FACP, FASCO (A): Stock and Ownership Interests- Pfizer (I); Consulting or Advisory Role- GlaxoSmithKline; Research Funding- Aduro Biotech (Inst); Lilly (Inst); Tesaro (Inst); Novartis (Inst); VBL Therapeutics (Inst); AstraZeneca (Inst)

Lainie P. Martin, MD (R): Consulting or Advisory Role- AstraZeneca, Sutro BioPharma, Elucida Oncology, GlaxoSmithKline; Research Funding- Agenus (Inst), AstraZeneca (Inst), Sutro BioPharma (Inst); Travel, Accommodations, Expenses- AstraZeneca

# ASCO-SEP<sup>®</sup>

Paul J. Sabbatini, MD (R, QW): Honoraria- UpToDate; Research Funding- Bristol-Myers Squibb (Inst), Ludwig Institute for Cancer Research (Inst)

Yi-Chun Lee, MD (QW): Consulting or Advisory Role- Tesaro; Research Funding- Tesaro (Inst), Xenetic Biosciences (Inst), NanOlogy (Inst), Genmab (Inst), AstraZeneca (Inst)

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 1.5 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.



# ASCO-SEP<sup>®</sup>

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 16 Melanoma and Other Skin Cancers

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of the basic epidemiology, natural history, and symptoms of melanoma and other skin cancers to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current treatment options for patients diagnosed with melanoma and other skin cancers and recommend approaches based on current evidence.

### Continuing Education Credit

2 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits™*
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHOR:

Katy K. Tsai, MD, University of California San Francisco, San Francisco, CA

## PEER REVIEWERS:

Sunandana Chandra, MD, Northwestern University, Evanston, IL

Zeynep Eroglu, MD, Moffitt Cancer Center, Tampa, FL

## QUESTION WRITERS AND REVIEWERS:

Sunandana Chandra, MD, Northwestern University, Evanston, IL

Zeynep Eroglu, MD, Moffitt Cancer Center, Tampa, FL

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Katy K. Tsai, MD (A): Consulting or Advisory Role- Regeneron, Bristol-Myers Squibb; Research Funding- Oncosec (Inst), Bristol Myers-Squibb (Inst), Regeneron (Inst), Array BioPharma (Inst), Parker Institute for Cancer Immunotherapy (Inst), Pfizer (Inst), Replimune (Inst), Genentech (Inst); Travel, Accommodations, Expenses- Bristol-Myers Squibb

Sunandana Chandra, MD (R, QW): Honoraria- Bristol-Myers Squibb, Array BioPharma, EMD Serono, Novartis, Pfizer, Sanofi/Regeneron, Exicure; Consulting or Advisory Role- Bristol-Myers Squibb, EMD

# ASCO-SEP<sup>®</sup>

Serono, Array BioPharma, Novartis, Pfizer, Sanofi/Regeneron, Exicure; Speakers' Bureau- Array BioPharma, Bristol-Myers Squibb Foundation, Sanofi/Regeneron

Zeynep Eroglu, MD (R, QW): Consulting or Advisory Role- Regeneron, SunPharma, Genentech/Roche, Novartis, OncoSec, Natera, Elsevier; Research Funding- Novartis (Inst), Pfizer (Inst)

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 2 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

# ASCO-SEP<sup>®</sup>

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 17 Sarcoma

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of the basic epidemiology, natural history, and symptoms of sarcoma to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current treatment options for patients diagnosed with sarcoma and recommend approaches based on current evidence.

### Continuing Education Credit

2 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits™*
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHOR:

Breelyn A. Wilky, MD, University of Colorado, Aurora, CO

## PEER REVIEWERS:

Elizabeth J. Davis, MD, Vanderbilt University, Nashville, TN

John A. Charlson, MD, Medical College of Wisconsin, Milwaukee, WI

## QUESTION WRITERS AND REVIEWERS:

Elizabeth J. Davis, MD, Vanderbilt University, Nashville, TN

John A. Charlson, MD, Medical College of Wisconsin, Milwaukee, WI

## **Disclosure of Relationships with Companies**

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Breelyn A. Wilky, MD (A): Honoraria- GlaxoSmithKline; Consulting or Advisory Role- Springworks, Deciphera, Adaptimmune, Daiichi Sankyo, Epizyme, Adcendo; Research Funding- Agenus, Exelixis; Travel, Accommodations, Expenses- Deciphera, Adaptimmune, Daiichi Sankyo

Elizabeth J. Davis, MD (R, QW): Honoraria- MJH Life Sciences; Consulting or Advisory Role- Deciphera; Speakers' Bureau- Physicians' Education Resource; Research Funding- Incyte (Inst), Five

# ASCO-SEP<sup>®</sup>

Prime Therapeutics (Inst), Genentech (Inst), Karyopharm Therapeutics (Inst), Bristol-Myers Squibb (Inst), Actuate (Inst), TopAlliance BioSciences (Inst)

John A. Charlson, MD (R, QW): Consulting or Advisory Role- Deciphera; Research Funding- Lilly (Inst)

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 2 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.



# ASCO-SEP<sup>®</sup>

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 18 Central Nervous System Tumors

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of the basic epidemiology, natural history, and symptoms of central nervous system tumors to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current treatment options for patients diagnosed with central nervous system tumors and recommend approaches based on current evidence.

### Continuing Education Credit

2 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*™
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHOR:

Stephen J. Bagley, MD, MSCE, University of Pennsylvania, Philadelphia, PA

## PEER REVIEWERS:

Wenyin Shi, MD, PhD, Jefferson Kimmel Cancer Center, Philadelphia, PA

Zachary A. Corbin, MD, MHS, Yale University, New Haven, CT

## QUESTION WRITERS AND REVIEWERS:

Wenyin Shi, MD, PhD, Jefferson Kimmel Cancer Center, Philadelphia, PA

Zachary A. Corbin, MD, MHS, Yale University, New Haven, CT

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Stephen J. Bagley, MD, MSCE (A): Consulting or Advisory Role- Novocure, Bayer, Sumitomo Dainippon Pharma Oncology; Research Funding- Incyte, Novocure, Lilly, Guardant Health, GlaxoSmithKline, Tempus, C2i Genomics; Patents, Royalties, Other Intellectual Property- Co-inventor of intellectual property of the University of Pennsylvania licensed to Novartis: Combination Therapies of EGFRvIII Chimeric Antigen Receptors and PD-1 Inhibitors; Travel, Accommodations, Expenses- Northwest Biotherapeutics

# ASCO-SEP<sup>®</sup>

Wenyin Shi, MD, PhD (R, QW): Consulting or Advisory Role- Novocure, Varian, BrainLAB, Zai Lab; Research Funding- Novocure (Inst), BrainLAB (Inst), Regeneron (Inst)

Zachary A. Corbin, MD, MHS (R, QW): No relationships to disclose

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 2 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

# ASCO-SEP<sup>®</sup>

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 19 Leukemias and Other Myeloid Neoplasms

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of the basic epidemiology, natural history, and symptoms of leukemias and other myeloid neoplasms to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current treatment options for patients diagnosed with leukemias and other myeloid neoplasms and recommend approaches based on current evidence.

### Continuing Education Credit

4.25 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*™
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHOR:

Matthew J. Wieduwilt, MD, PhD, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK

Maximilian Stahl, MD, Dana-Farber Cancer Institute, Boston, MA

## PEER REVIEWERS:

Camille N. Abboud, MD, Siteman Cancer Center, St. Louis, MO

Jane L. Liesveld, MD, University of Rochester Medical Center, Rochester, NY

## QUESTION WRITERS AND REVIEWERS:

Camille N. Abboud, MD, Siteman Cancer Center, St. Louis, MO

Jane L. Liesveld, MD, University of Rochester Medical Center, Rochester, NY

Nosha Farhadfar, MD, University of Florida, Gainesville, FL

Reshma Ramlal, MD, University of Kentucky, Lexington, KY

Zaid Abdel Rahman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

## **Disclosure of Relationships with Companies**

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

# ASCO-SEP<sup>®</sup>

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Matthew J. Wieduwilt, MD, PhD (A): Stock and Ownership Interests- Reata Pharmaceuticals; Honoraria- Gilead, SERVIER; Consulting or Advisory Role- Gilead, SERVIER; Research Funding- NCI (Inst)

Maximilian Stahl, MD (A): No relationships to disclose

Camille N. Abboud, MD (R, QW): Stock and Ownership Interests: Abbvie (I), Abbott Laboratories (I), Gilead Sciences (I), Bristol-Myers Squibb (I), Johnson & Johnson (I); Consulting or Advisory Role- ArcherDX; Research Funding- Actinium Pharmaceuticals, Selvita (Inst), Forty Seven(Inst)

Jane L. Liesveld, MD (R, QW): Consulting or Advisory Role- Bristol-Myers Squibb Foundation, Blueprint Medicines; Other Relationship- Oconova, Syros

Nosha Farhadfar, MD (QW): Consulting or Advisory Role- Incyte Pharma; Research Funding- CSL Behring (Inst)

Reshma Ramlal, MD (QW): No relationships to disclose

Zaid Abdel Rahman, MD (QW): No relationships to disclose

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 4.25 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.



# ASCO-SEP<sup>®</sup>

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 20 Lymphomas

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of the basic epidemiology, natural history, and symptoms of lymphoma to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current treatment options for patients diagnosed with lymphomas and recommend approaches based on current evidence.

### Continuing Education Credit

3 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits™*
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHOR:

Stephen D. Smith, MD, Seattle Cancer Care Alliance, Seattle, WA

## PEER REVIEWERS:

Erin Reid, MD, University of California- San Diego, San Diego, CA

Mauro C. Janoski, MD, Providence-St Joseph Cancer Center, Eureka, California

## QUESTION WRITERS AND REVIEWERS:

Erin Reid, MD, University of California- San Diego, San Diego, CA

Inas Abuali, MD, Massachusetts General Hospital, Boston, MA

Jonathon Cohen, MD, MS, Winship Cancer Institute of Emory University, Atlanta, GA

Mauro C. Janoski, MD, Oncology Institute of Hope and Innovation, Hemet, CA

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Stephen D. Smith, MD (A): Consulting or Advisory Role- AstraZeneca, Millenium/Takeda, Karyopharm Therapeutics, Kite, Incyte, ADC Therapeutics, BeiGene; Research Funding- Ayala Pharmaceuticals (I),

# ASCO-SEP<sup>®</sup>

Bristol-Myers Squibb (I), Acerta Pharma/AstraZeneca (Inst), Bayer (Inst), Denovo Biopharma (Inst), Genentech (Inst), Ignyta (Inst), Incyte (Inst), Merck (Inst), Portola Pharmaceuticals (Inst)

Erin Reid, MD (R, QW): Employment- EpicentRx (I); Leadership- EpicentRx (I); Stock and Ownership Interests- EpicentRx (I); Research Funding- ADC Therapeutics (Inst), Aptose Biosciences (Inst), Millenium Pharmaceuticals (Inst), Abbvie (Inst), Xencor (Inst); Patents, Royalties, Other Intellectual Property- Husband holds multiple patents related to lymphedema management, oncolytic viral therapy.(I)

Mauro C. Janoski, MD (R, QW): Consulting or Advisory Role- Cardinal Health, AmerisourceBergen, Curio Science, DAVA Pharmaceuticals, Cor2Ed

Inas Abuali, MD (QW): No relationships to disclose

Jonathon Cohen, MD, MS (QW): Consulting or Advisory Role- Abbvie, Janssen, Loxo Oncology, Kite/Gilead, AstraZeneca, Aptitude, Adicet, Adaptive Biotechnologies; Research Funding- Bristol-Myers Squibb (Inst), Janssen (Inst), Novartis (Inst), Takeda (Inst), AI Therapeutics (Inst), Genentech (Inst), ASH (Inst), Lymphoma Research Foundation (Inst), Loxo Oncology (Inst), Bioinvent (Inst), AstraZeneca (Inst)

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 3 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

# ASCO-SEP<sup>®</sup>

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 21 Multiple Myeloma

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of the basic epidemiology, natural history, and symptoms of multiple myeloma to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current treatment options for patients diagnosed with multiple myeloma and recommend approaches based on current evidence.

### Continuing Education Credit

1.5 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits*™
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHORS:

Cindy Varga, MD, Levine Cancer Institute, Charlotte, NC

Joseph Mikhael, MD, MEd, FRCPC, FACP, City of Hope Cancer Center, Phoenix, AZ

## PEER REVIEWERS:

Alfred L. Garfall, MD, University of Pennsylvania, Philadelphia, PA

Erica L. Campagnaro, MD, Rogel Cancer Center, University of Michigan, Ann Arbor, MI

## QUESTION WRITERS AND REVIEWERS:

Alfred L. Garfall, MD, University of Pennsylvania, Philadelphia, PA

Nosha Farhadfar, MD, University of Florida, Gainesville, FL

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Cindy Varga, MD (A): Honoraria- Adaptive Biotechnologies

Joseph Mikhael, MD, MEd, FRCPC, FACP (A): Honoraria- Amgen, Karyopharm Therapeutics, Sanofi, Janssen, Celgene, GlaxoSmithKline, Takeda, Oncopeptides

# ASCO-SEP<sup>®</sup>

Alfred L. Garfall, MD (R, QW): Stock and Ownership Interests- Cabaletta Bio; Consulting or Advisory Role- Janssen Oncology, GlaxoSmithKline, Amgen; Research Funding- Novartis (Inst), Tmunity Therapeutics (Inst), Janssen Oncology (Inst), Crispr Therapeutics (Inst); Patents, Royalties, and Other Intellectual Property- Patent in the field of CAR T cell therapy

Erica L. Campagnaro, MD (R): No relationships to disclose

Nosha Farhadfar (QW): Consulting or Advisory Role- Incyte Pharma; Research Funding- CSL Behring (Inst)

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 1.5 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.



# ASCO-SEP<sup>®</sup>

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.



## Chapter 22 Cellular Therapies

### Description

ASCO-SEP® is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology and provide a current understanding of cancer, its treatment, and the supportive care needed to optimize the quality of life for people with cancer.

### Learning Objectives

- Apply knowledge learned of basic cellular therapies to patient care.
- Evaluate appropriate imaging and other diagnostic techniques to accurately identify and stage cancer.
- Compare current cellular therapy treatment options for patients diagnosed with cancer and recommend approaches based on current evidence.

### Continuing Education Credit

1.5 credits / points are available for participation in this course.

Certificates and credit types available include

- *AMA PRA Category 1 Credits™*
- ABIM MOC Points
- Certificate of Participation
- Certificate of Completion

### Credit Expiration

This activity expires on 05/31/2023. Learners must complete all necessary components by this date to receive credit.

#### EDITOR-IN-CHIEF:

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

#### ASSOCIATE EDITORS:

Krishna C. Alluri, MD, St. Luke's Cancer Institute, Boise, ID

Elie G. Dib, MD, FACP, St. Joseph Mercy Cancer Center, Ann Arbor, MI

Jill Lacy, MD, Yale University, New Haven, CT

Tara Mitchell, MD, University of Pennsylvania, Philadelphia, PA

# ASCO-SEP<sup>®</sup>

## AUTHOR:

Eric J. Huselton, MD, University of Rochester, Rochester, NY

Michael W. Becker, MD, University of Rochester, Rochester, NY

## PEER REVIEWERS:

Brittany K. Ragon, MD, Levine Cancer Institute, Charlotte, NC

Iris Isufi, MD, Yale University, New Haven, CT

## QUESTION WRITERS AND REVIEWERS:

Brittany K. Ragon, MD, Levine Cancer Institute, Charlotte, NC

Zaid Abdel Rahman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

## Disclosure of Relationships with Companies

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution). Disclosures are submitted per the [ASCO Policy for Relationships with Companies](#).

*Contributor roles are indicated as follows: EB = Editorial Board, A = Author and Question Reviewer, R = Reviewer, QW = Question Writer*

Benjamin Levy, MD (EB): Consulting or Advisory Role- Lilly, Genentech/Roche, AstraZeneca, Pfizer, Merck, Takeda, Guardant Health, Novartis, Daiichi Sankyo/AstraZeneca; Research Funding- Loxo (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Turning Point Therapeutics (Inst), Merck (Inst)

Jill Lacy, MD (EB): Consulting or Advisory Role- Sirtex Medical, Celgene, KeyQuest Health, Navigant Consulting, AstraZeneca, Merck, Ipsen, Decipher, Guidepoint Global, Bionest Partners, Aptitude Health, Novartis, Techspert.io; Travel, Accommodations, Expenses- Lilly

Tara Mitchell, MD (EB): Consulting or Advisory Role- Bristol-Myers Squibb, Merck, OncoSec, GigaGen; Research Funding- Merck (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst), Roche (Inst); Travel, Accommodations, Expenses- Merck, Bristol-Myers Squibb

Elie G. Dib, MD (EB): No relationships to disclose

Krishna C. Alluri, MD (EB): Stock and Ownership Interests- Abbvie, Biogen, Celgene, Gilead Sciences

Eric J. Huselton, MD (A): No relationships to disclose

Michael W. Becker, MD (A): No relationships to disclose

# ASCO-SEP<sup>®</sup>

Brittany K. Ragon, MD (R, QW): No relationships to disclose

Iris Isufi, MD (R): Consulting or Advisory Role- Celgene/Jazz, Kite Pharma, Epizyme, Beam Therapeutics, ADC Therapeutics; Speakers' Bureau- Kite

Zaid Abdel Rahman, MD (QW): No relationships to disclose

## **Commercial Support**

This activity was supported by ASCO Education. No funds or in-kind contributions from commercial entities were used for support.

## **Joint Accreditation Statement**

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **AMA Credit Designation Statement - Physicians**

The American Society of Clinical Oncology designates this enduring material for a maximum of 1.5 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Maintenance of Certification - ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

## **Obtaining Credit and Requesting Certificates**

A certificate confirming Continuing Medical Education (CME) credits received is available for print and/or download after completing the evaluation and submitting the request for credit. Nonphysician participants are welcome to submit a request for a Certificate of Participation, which may enable nonphysicians to apply their participation in this course toward re-licensure. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted. A Certificate of Completion is available to all participants but does not award any credit and does not note any specific amount of participation in this activity.

# ASCO-SEP<sup>®</sup>

## **Disclaimer / Unlabeled Usage Statement**

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.